Showing 1311-1320 of 10817 results for "".
Avoid the Three Most Common Asset Protection Mistakes
https://practicaldermatology.com/topics/practice-management/avoid-the-three-most-common-asset-protection-mistakes/18368/OJM Group principal David Mandell, JD, MBA discusses the importance of protecting personal and business assets from lawsuits, and outlines strategies to avoid the three asset protection mistakes made by most doctors. Click here to request or download a free copy of Wealth Protection Planning for DeItching for Answers: Understanding and Treating Pruritus
https://practicaldermatology.com/topics/general-topics/itching-for-answers-understanding-and-treating-pruritus/18493/Since childhood, when he was affected by eczema and associated pruritus, Ethan Lerner, MD, PhD has been fascinated by itch, its causes, and its potential treatments. In this edition of Benchside Dispatches, he offers a fresh look at the latest research on pruritus and the challenges facing scientistUpdate on Pediatric Vulvar Lichen Sclerosis
https://practicaldermatology.com/topics/general-topics/update-on-pediatric-vulvar-lichen-sclerosis/18733/Pediatric vulvar lichen sclerosis may be under-recognized. Pediatric dermatologist Kalyan Marathe, MD talks to host Adam Friedman, MD about the importance of identifying and treating the condition, providing relief to patients and potentially avoiding unnecessary testing.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oAcne Update: A Review of New Guidelines, Treatment Advances, and Drugs in the Pipeline
https://practicaldermatology.com/topics/general-topics/acne-update-a-review-of-new-guidelines-treatment-advances-and-drugs-in-the-pipeline/18773/Linda Stein Gold, MD talks to DermTube Journal Club Host Joshua Zeichner, MD about the new acne treatment guidelines recently published in the Journal of the American Academy of Dermatology. She discusses the process of developing the guidelines and highlights some of what's new, such as new, limiteGold's Standards: Nashville's Laser Guru on Best Practices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/gold-s-standards-nashville-s-laser-guru-on-best-practices/18867/When a third of your practice is dedicated to energy-based devices, it's important to find the best solutions for your patient flow. In this edition of Best Practices, Joel L. Cohen, MD talks to Michael H. Gold, MD about his approach to adoption and promotion of energy-based devices. Dr. Gold discusStarting a Practice: Choosing Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/starting-a-practice-choosing-devices/18900/In his new series for Modern Aesthetics® Magazine, Christopher Khorsandi, MD offers tips for aesthetic physicians opening or expanding a practice. In this edition he discusses device selection and integration with an emphasis on marketing and patient conversion.Update on Melanoma Detection and Screening
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-on-melanoma-detection-and-screening/19095/From full body skin exams to emerging tape-strip methods for melanoma diagnosis, Laura Ferris, MD talks about the latest research in skin cancer diagnosis with host Joshua Zeichner, MD.Novel Approaches to Nonmelanoma Skin Cancer
https://practicaldermatology.com/topics/skin-cancer-photoprotection/novel-approaches-to-nonmelanoma-skin-cancer/23696/New and emerging treatment options are advancing care for patients with NMSC.What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis
https://practicaldermatology.com/topics/psoriasis/what-does-efficacy-cost-evidence-for-relative-cost-effectiveness-of-biologic-therapies-for-psoriasis/23128/Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.